Beyond analysts' top -and-bottom-line estimates for Alnylam (ALNY), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ...

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Free Report) has received an average recommendation of “Moderate Buy” from ...

SG Americas Securities LLC cut its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 50.8% ...

Liquidity indicates a company’s capability to meet debt obligations by converting its assets into liquid cash and equivalents. A company with adequate liquidity always has the potential to deliver ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The United States market has shown robust performance recently, climbing 3.0% in the last week and achieving a 25% increase over the past year, with earnings expected to grow by 15% annually. In this ...

Alnylam Pharmaceuticals (Alnylam) is a biopharmaceutical company, which discovers, develops, and commercializes drugs based on RNAi interference. The company’s marketed RNAi therapies include Onpattro ...

Long-term treatment with patisiran (Onpattro) led to modest changes for ... Medical writing of this study was funded by Alnylam Pharmaceuticals. Adams reported consulting fees from Alnylam ...

Alnylam's CEO, Yvonne Greenstreet ... "ALNY preannounced 4Q24/FY24 Onpattro/Amvuttra revs of $56M/$287M and $253M/$970M, respectively, beating cons. Givlaari 4Q24/FY24 revenues of $65M/$256M slightly ...